glp-1 obesity drug news today september 29 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1s and Obesity Coverage: Differing

Thursdays readout could cast an even longer shadow of doubt over Novos obesity pipeline, particularly after the disappointing Phase II results for its small molecule oral cannabinoid receptor 1 agonist monlunabant, which in September showed modest weight reductions muddied by psychiatric side effects

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure

These belong to a class of drugs called incretin mimetics , which either mimic or enhance the effects of gut hormones that regulate appetite and metabolism

ALCAR supplements can help restore carnitine levels and exert several benefits